AGIOS PHARMACEUTICALS, INC.
AGIOLoading price...
Overview
Previous Close29.61
Open33.73
Ask43.49
Bid25.77
Day's Range33.67 - 36.35
52 Week Range22.24 - 46.00
PE Ratio(TTM)--
Market Cap1.98B
Volume3.55M
Avg. Volume868.31k
12 Months Earnings-412.78M
12 Months Revenue54.03M
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Operating Revenue | 54.03M | 54.03M | 40.88M | 36.50M | 26.82M | 14.24M |
| Cost of Revenue | 6.34M | 6.34M | 4.83M | 4.17M | 2.88M | 1.70M |
| Gross Profit | 47.68M | 47.68M | 36.05M | 32.33M | 23.94M | 12.54M |
| Operating Expenses | 519.82M | 519.82M | 497.58M | 458.07M | 415.43M | 401.58M |
| Profit after Tax (Net Income) | -412.78M | -412.78M | 650.08M | 673.73M | -352.09M | -231.80M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Cambridge, United States
Website: https://www.agios.com
CEO & Director: Mr. Brian M. Goff M.B.A.
Employees: 539
About Company:
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.